Excelsior Biopharma (6496) — Cash Flow Quality Index
Excelsior Biopharma (6496) has a Cash Flow Quality Index of -3.02x as of December 2023. Operating cash flow of NT$-25.78 Million is below net income of NT$8.54 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore 6496 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Excelsior Biopharma Cash Flow Quality Index (2017–2020)
Historical Cash Flow Quality Index for Excelsior Biopharma across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 6496 cash generation efficiency.
Annual Cash Flow Quality Index for Excelsior Biopharma (2017–2020)
Year-by-year earnings quality comparison for Excelsior Biopharma.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2020 | 11.50x | NT$520.81 Million | NT$45.30 Million | ▲ +581.0% |
| 2019 | -2.39x | NT$-169.74 Million | NT$71.01 Million | ▼ -517.8% |
| 2018 | 0.57x | NT$126.92 Million | NT$221.83 Million | ▼ -54.2% |
| 2017 | 1.25x | NT$349.47 Million | NT$279.68 Million | — |